Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 5Completed 4Recruiting 3Not yet recruiting 2Unknown 1Enrolling by invitation 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Other solid neoplasm 1Gastrointestinal 1Breast 1

Conditions

Breast Neoplasms 3Glioma 2Esophageal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Adenoviridae Infections 2Uveal Melanoma 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumors 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neurofibrosarcoma 1Neuroblastoma 1Neoplasms 1Multiple Myeloma 1Metastatic Castration-resistant Prostate Cancer 1Mesothelioma, Malignant 1Melanoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, B-Cell 1Graft vs Host Disease 1Glioblastoma 1Gastro-enteropancreatic neuroendocrine tumor 1Esophageal Squamous Cell Carcinoma 1Epstein-Barr Virus Infections 1Cytomegalovirus Infections 1Colorectal Neoplasms 1Cholangiocarcinoma 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Enrolling by invitation × Neurofibrosarcoma × Clear all
NCT06603987 2025-11-19

Using CICS-1 and SPM-011 and ï¼»18Fï¼½FBPA Commissioned by CICS and Sumitomo Heavy Industries and STELLA PHARMA

Stella Pharma Corporation

Phase 1/2 Enrolling by invitation
30 enrolled
BreastGastrointestinalOther solid neoplasmSarcomaThoracic

Mesothelioma, Malignant, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Neurofibrosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡